Activating mutations in the HER2/ERBB2 gene are another mechanism of resistance to HER2-directed therapies; these are found in around 2–3% of all breast cancers and are associated with a worse prognosis (Figure 2B) [46]. The gene discussed is ERBB2; the disease is breast carcinoma.